Xinxing Ma

Title: Xinxing Ma: Innovator in Anti-Angiogenesis Fusion Proteins

Introduction

Xinxing Ma is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of anti-angiogenesis fusion proteins. His innovative work aims to address critical health challenges related to tumor growth and vascular diseases.

Latest Patents

Xinxing Ma holds a patent for a novel anti-angiogenesis fusion protein. This invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component. The fusion protein exhibits superior binding capacity with human VEGF and placental growth factor (PIGF). It boasts improved stability, a prolonged half-life, and the ability to form multivalent interactions with VEGF. This innovation has potential applications in anti-angiogenesis, treating VEGF-related diseases, and inhibiting tumor growth.

Career Highlights

Xinxing Ma is associated with Genor Biopharma Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biotechnology sector, contributing to the understanding and treatment of complex diseases.

Collaborations

Xinxing Ma collaborates with notable colleagues, including Joe Zhou and Jianyang Zhao. Their combined expertise enhances the research and development initiatives at Genor Biopharma Co., Ltd.

Conclusion

Xinxing Ma's innovative contributions to anti-angiogenesis fusion proteins highlight his role as a leading inventor in biotechnology. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in the treatment of various diseases.